Search | Clinical Trials Finder

Conditions: Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent
Interventions: Docetaxel, Tergenpumatucel-L, Indoximod; Drug · Biological
Lead sponsor: NewLink Genetics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: St Louis, Missouri • Cincinnati, Ohio

Conditions: ALK Gene Rearrangement, Lung Non-Small Cell Carcinoma, Progressive Disease, ROS1 Gene Rearrangement, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer
Interventions: Binimetinib, Brigatinib; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: End of Life, Cancer
Interventions: Receive technology-based supportive cancer care, Receive redesigned team-based supportive cancer care; Other · Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 2,996 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 17
States / cities: Birmingham, Alabama • Mobile, Alabama • Duarte, California + 11 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Dacomitinib (PF-00299804), Active Comparator (erlotinib), Placebo erlotinib, Placebo PF00299804; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 878 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 107
States / cities: Birmingham, Alabama • Florence, Alabama • Mobile, Alabama + 65 more

Conditions: Advanced or Metastatic Non-small Cell Lung Cancer
Interventions: Lazertinib, Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF), Amivantamab Intravenous; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Duarte, California • Irvine, California • Long Beach, California + 13 more

Conditions: Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer, Non Small Cell Lung Carcinoma
Interventions: azacytidine, carboplatin, paclitaxel, durvalumab, cisplatin, gemcitabine, pemetrexed; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Placebo, Erlotinib, Second-Line Chemotherapy; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 9
States / cities: Gilroy, California • Washington D.C., District of Columbia • Kansas City, Missouri + 6 more

Conditions: Advanced or Metastatic Solid Tumor
Interventions: PLN-101095, Pembrolizumab; Drug
Lead sponsor: Pliant Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 6
States / cities: New Haven, Connecticut • Atlanta, Georgia • Grand Rapids, Michigan + 3 more

Conditions: Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Metastases, Neoplasm
Interventions: Motexafin Gadolinium; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 44
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 41 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Alectinib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 45
States / cities: Bimingham, Alabama • Daphne, Alabama • Mobile, Alabama + 35 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Ramucirumab, Placebo (for Ramucirumab), Docetaxel; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 97
States / cities: Phoenix, Arizona • Sedona, Arizona • Fayetteville, Arkansas + 93 more

Conditions: Carcinoma, Non-Small-Cell-Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
Interventions: PDR001, ACZ885, CJM112, TMT212, EGF816; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 4
States / cities: Baltimore, Maryland • Boston, Massachusetts • Nashville, Tennessee + 1 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Iza-bren, Carboplatin, Cisplatin, Pemetrexed; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 28
States / cities: Irvine, California • Orange, California • Edwards, Colorado + 22 more

Conditions: Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Merkel Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Atezolizumab, Avelumab, Durvalumab, Nivolumab, Pembrolizumab, Plinabulin, Radiation Therapy; Biological · Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Stage 4 NSCLC, Radiotherapy
Interventions: Prophylactic Palliative Radiotherapy; Radiation
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Non-small Cell Lung Cancer
Interventions: BNT326, BNT327, Pembrolizumab, SoC; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 9
States / cities: Stanford, California • New Haven, Connecticut • Tampa, Florida + 6 more

Conditions: Metastatic Non-Squamous Non-Small Cell Lung Cancer
Interventions: Nivolumab, Sitravatinib, Docetaxel; Biological · Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 577 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 133
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 109 more

Conditions: Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
Interventions: Durvalumab, Radiation Therapy, Biospecimen Collection; Biological · Radiation · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Elastography, Multigated Acquisition Scan, Necitumumab, Osimertinib; Procedure · Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 15
States / cities: Duarte, California • Palo Alto, California • Sacramento, California + 7 more

Conditions: Non-small Cell Lung Cancer
Interventions: Atezolizumab and Interleukin-12 Gene Therapy; Combination Product
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-small Lung Cancer
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Non-Small-Cell Lung Cancer
Interventions: CAB-AXL-ADC, PD-1 inhibitor; Biological
Lead sponsor: BioAtla, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 32
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 26 more

Conditions: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Placebo, RG1507, erlotinib [Tarceva]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 15
States / cities: Beverly Hills, California • New Port Richey, Florida • Atlanta, Georgia + 10 more

Search by objective public record fields.

Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy

Afatinib Genomic Landscape

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).